UPDATE: Cipher Pharmaceuticals Upgraded to Buy at Stifel GMP; Price Target Raised to C$8.00

For those interested

Keep hiking those price targets after the stock runs 60% higher than your prior target, boys.

With Terclara less than a year out from the end of its final phase 3 trial & Cipher Pharmaceuticals already recognizing its future sales against their NOL’s, you would think that this would start getting priced into the stock. But I guess Stifel expects Cipher to go through dramatic multiple compression.